A Phase II Study Evaluating Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
Latest Information Update: 14 Mar 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Telatinib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Liver cancer; Oesophageal cancer
- Focus Therapeutic Use
- 28 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2022 Status changed from active, no longer recruiting to recruiting.
- 24 Apr 2022 Status changed from recruiting to active, no longer recruiting.